Chunyan Sun

2.6k total citations
102 papers, 1.6k citations indexed

About

Chunyan Sun is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Chunyan Sun has authored 102 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Molecular Biology, 41 papers in Hematology and 31 papers in Oncology. Recurrent topics in Chunyan Sun's work include Multiple Myeloma Research and Treatments (35 papers), Peptidase Inhibition and Analysis (15 papers) and Protein Degradation and Inhibitors (14 papers). Chunyan Sun is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Peptidase Inhibition and Analysis (15 papers) and Protein Degradation and Inhibitors (14 papers). Chunyan Sun collaborates with scholars based in China, United States and Austria. Chunyan Sun's co-authors include Yu Hu, Fengjuan Fan, Lisha Ai, Zhang‐Bo Chu, You Qin, Lei Chen, Shidai Mu, Tao Guo, Aoshuang Xu and Huafang Wang and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Chunyan Sun

90 papers receiving 1.6k citations

Peers

Chunyan Sun

ONCOL

HEMAT

IMMUN

Shan‐Chi Liu Taiwan

Chen‐Ming Su Taiwan

Luca Beltrame Italy

Ilaria Canobbio Italy

Lina Hu China

Jiangchao Li China

Zia Shariat‐Madar United States

Tao Sun China

Yan Ru Su United States

Ian M. Rogers Canada

Shan‐Chi Liu Taiwan

Chunyan Sun

895 ×0.9

343 ×0.8

315 ×0.9

ONCOL

79 ×0.2

HEMAT

299 ×1.7

IMMUN

Citations per year, relative to Chunyan Sun Chunyan Sun (= 1×) peers Shan‐Chi Liu

Countries citing papers authored by Chunyan Sun

Since Specialization

Citations

This map shows the geographic impact of Chunyan Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunyan Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunyan Sun more than expected).

Fields of papers citing papers by Chunyan Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunyan Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunyan Sun. The network helps show where Chunyan Sun may publish in the future.

Co-authorship network of co-authors of Chunyan Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Chunyan Sun. A scholar is included among the top collaborators of Chunyan Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunyan Sun. Chunyan Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Chi, Aoshuang Xu, Liping Zuo, et al.. (2025). Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential. Pharmaceuticals. 18(5). 640–640.

Li, Qun, et al.. (2025). Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis. Annals of Medicine. 57(1). 2560679–2560679.

Chen, Lei, et al.. (2025). Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in vitro effects. Carcinogenesis. 46(2).

Wang, Xuezhu, Liping Zuo, Jian Xu, et al.. (2025). Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis. Genomics Proteomics & Bioinformatics. 23(2).

Wang, Guangqi, et al.. (2025). Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias. Blood. 146(Supplement 1). 5789–5789.

Huang, Xing, Chunyan Sun, Peng Zhang, & Lei Wang. (2024). Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience. BMC Urology. 24(1). 289–289.

Shen, Kaini, et al.. (2024). Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study. Blood. 144(Supplement 1). 893–893.

Zhao, Fei, et al.. (2023). Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis. International Immunopharmacology. 126. 111277–111277.

Zhang, Jiasi, Yuxi Liu, Qun Li, et al.. (2023). ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis. Carcinogenesis. 44(3). 242–251. 22 indexed citations

10.

Liu, Huiwen, Honglan Wang, Qiyu Li, et al.. (2023). LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment. Acta Pharmaceutica Sinica B. 13(9). 3817–3833. 16 indexed citations

11.

Gao, Su, Aoshuang Xu, Liping Zuo, et al.. (2023). MALAT1 regulates network of microRNA-15a/16–VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma. Carcinogenesis. 44(10-11). 760–772. 9 indexed citations

12.

Sun, Chunyan, Guangxun Gao, Fuling Zhou, et al.. (2023). Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4763–4763. 1 indexed citations

13.

Yin, Xuejiao, Fengjuan Fan, Bo Zhang, Yu Hu, & Chunyan Sun. (2022). Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Therapeutic Advances in Hematology. 13. 1554004515–1554004515. 15 indexed citations

14.

Sun, Chunyan, Xiaohong Wang, Renyi Zhang, et al.. (2022). Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis. Cancer Cell International. 22(1). 222–222. 6 indexed citations

15.

Xu, Aoshuang, Jiasi Zhang, Liping Zuo, et al.. (2021). FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. Molecular Therapy. 30(3). 1104–1118. 50 indexed citations

16.

Wang, Honglan, Huiwen Liu, Chunyan Sun, et al.. (2021). Nanoparticles Dual Targeting Both Myeloma Cells and Cancer-Associated Fibroblasts Simultaneously to Improve Multiple Myeloma Treatment. Pharmaceutics. 13(2). 274–274. 12 indexed citations

17.

Yin, Xuejiao, Aoshuang Xu, Fengjuan Fan, et al.. (2020). A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes. Frontiers in Oncology. 10. 566–566. 4 indexed citations

18.

Yin, Xuejiao, Lei Chen, Fengjuan Fan, et al.. (2020). Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study. Frontiers in Oncology. 10. 1712–1712. 14 indexed citations

19.

Chu, Zhang‐Bo, Chunyan Sun, Di Yang, Lei Chen, & Yu Hu. (2013). Role of brain-derived neurotrophic factor in bone marrow angiogenesis in multiple myeloma. Journal of Huazhong University of Science and Technology [Medical Sciences]. 33(4). 485–490. 5 indexed citations

20.

Sun, Chunyan, You Qin, Zhang‐Bo Chu, et al.. (2012). miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 34(2). 426–435. 179 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact